

REFERENCES

1. AP News. (2024). FDA Has Massive Backlog of Factory Inspections as Staffers Leave for Private Sector Jobs. September 5. <https://apnews.com/article/fda-inspections-drug-manufacturing-india-china-7b3a7e9b45b-cc3aea86ce5bf781271f3>
2. Kearney A., G. Sparks, L. Hamel, J. Montalvo III, I. Valdes and A. Kirzinger. (2025). KFF Tracking Poll on Health Information and Trust: January 2025. KFF. <https://www.kff.org/health-information-and-trust/poll-finding/kff-tracking-poll-on-health-information-and-trust-january-2025>
3. Perlis R. H., K. Ognyanova, A. Uslu. (2024). Trust in Physicians and Hospitals During the COVID-19 Pandemic in a 50-State Survey of US Adults. *JAMA Network Open*, 7 (7): e2424984. doi:10.1001/jamanetworkopen.2024.24984
4. *Loper Bright Enterprises v. Raimondo*. S. Ct. 144, 2244 (Supreme Court 2024).
5. *Corner Post v. Bd of Gov of Federal Reserve Sys*. S. Ct. 144, 2440 (Supreme Court 2024).
6. Todd L., and S. Todd. (2025). FDA Commissioner Marty Makary Gets Off to a Bruising Start as Agency Is Wracked by Layoffs. *STAT*, April 1. <https://www.statnews.com/2025/04/01/fda-rif-3500-layoff-notice-under-rfk-jr-hhs-reorganization>
7. Karins J., and J. Brown. (2025). HHS Floats Major FDA Reorganization That Would Merge All Product Centers. Inside Health Policy. April 4. <https://insidehealthpolicy.com/daily-news/hhs-floats-major-fda-reorganization-would-merge-all-product-centers>
8. Hopkins J. (2025). After FDA Cuts, Drug Development Is Slowing Down. *Wall Street Journal*. April 17. <https://www.wsj.com/health/healthcare/drug-development-is-slowing-down-after-cuts-at-the-fda-f22369cf>
9. FDA. (2023). Report to Congress: Drug Shortages CY 2023. <https://www.fda.gov/media/179156/download>
10. Mulcahy A.W., D. Schwam and S.L. Lovejoy. (2024). International Prescription Drug Price Comparisons: Estimates Using 2022 Data. RAND Corporation. https://www.rand.org/pubs/research_reports/RRA788-3.html
11. U.S. Congress. (1938). 21 USC 393(b): Food and Drug Administration Mission. Vol. 21. [https://uscode.house.gov/view.xhtml?req=\(title:21%20section:393%20edition:prelim\)%20OR%20\(granuleid:USC-prelim-title21-section393\)&f=treesort&edition=prelim&num=0&jumpTo=true#substructure-location_b](https://uscode.house.gov/view.xhtml?req=(title:21%20section:393%20edition:prelim)%20OR%20(granuleid:USC-prelim-title21-section393)&f=treesort&edition=prelim&num=0&jumpTo=true#substructure-location_b)
12. Sachs R.E., W.N. Price and P.J. Zettler. (2024). Rethinking Innovation at FDA. *Boston University Law Review*, 104: 513
13. Gottlieb S. (2018). Opening Remarks for Part 15 Public Meeting on Generic Drug Competition. FDA. <https://www.fda.gov/news-events/speeches-fda-officials/opening-remarks-part-15-public-meeting-generic-drug-competition-07182018>
14. Schad F., and A. Thronicke. (2022). Real-World Evidence: Current Developments and Perspectives. *International Journal of Environmental Research and Public Health*, 19 (16): 10159. doi:10.3390/ijerph191610159
15. Sverdlov, O., Y. Ryznik and W.K. Wong. (2021). Opportunity for Efficiency in Clinical Development: An Overview of Adaptive Clinical Trial Designs and Innovative Machine Learning Tools, With Examples From the Cardiovascular Field. *Contemporary Clinical Trials*, 105: 106397. doi:10.1016/j.cct.2021.106397
16. FDA. (2023). Draft Guidance for Industry: Demonstrating Substantial Evidence of Effectiveness With One Adequate and Well-Controlled Clinical Investigation and Confirmatory Evidence. <https://www.fda.gov/media/172166/download>
17. Franklin J.M., and S. Schneeweiss. When and How Can Real World Data Analyses Substitute for Randomized Controlled Trials? *Clinical Pharmacology & Therapeutics*, 102 (6): 924-33. doi:10.1002/cpt.857
18. BIO, Informa Pharma Intelligence and QLS Advisors. (2021). Clinical Development Success Rates and Contributing Factors 2011-2020. <https://www.bio.org/clinical-development-success-rates-and-contributing-factors-2011-2020>
19. Wouters O.J., M. McKee and J. Luyten. (2020). Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018. *JAMA*, 323 (9): 844-53. doi:10.1001/jama.2020.1166
20. Bates S.E., D.A. Berry, S. Balasubramaniam, S. Bailey, P.M. LoRusso and E.H. Rubin. Advancing Clinical Trials to Streamline Drug Development. *Clinical Cancer Research*. 21 (20): 4527-35. doi:10.1158/1078-0432.CCR-15-0039
21. Burcu M., N.A. Dreyer, J.M. Franklin et al. (2020). Real-World Evidence to Support Regulatory Decision-Making for Medicines: Considerations for External Control Arms. *Pharmacoepidemiology and Drug Safety*, 29 (10): 1228-35. doi:10.1002/pds.4975
22. Khozin S., and A. Coravos. (2019). Decentralized Trials in the Age of Real-World Evidence and Inclusivity in Clinical Investigations. *Clinical Pharmacology and Therapeutics*, 106 (1): 25-27. doi:10.1002/cpt.1441
23. Campbell U.B., N. Honig and N.M. Gatto. (2023). SURF: A Screening Tool (for Sponsors) to Evaluate Whether Using Real-World Data to Support an Effectiveness Claim in an FDA Application Has Regulatory Feasibility. *Clinical Pharmacology & Therapeutics*, 114 (5): 981-93. doi:10.1002/cpt.3021
24. U.S. Congress. 21st Century Cures Act, 2016.
25. FDA. (2023). Draft Guidance for Industry: Demonstrating Substantial Evidence of Effectiveness With One Adequate and Well-Controlled Clinical Investigation and Confirmatory Evidence. <https://www.fda.gov/media/172166/download>

26. FDA. (2023). Draft Guidance for Industry: Master Protocols for Drug and Biological Product Development. <https://www.fda.gov/media/174976/download>
27. FDA. (2019). Guidance for Industry: Adaptive Designs for Clinical Trials of Drugs and Biologics. <https://www.fda.gov/media/78495/download>
28. FDA. (2010). Guidance for Industry and FDA Staff: Guidance for the Use of Bayesian Statistics in Medical Device Clinical Trials.
29. FDA. (2024). Guidance for Industry, Investigators, and Other Interested Parties: Conducting Clinical Trials With Decentralized Elements Guidance for Industry, Investigators, and Other Interested Parties.
30. FDA. (2024). Guidance for Industry: Real-World Data: Assessing Electronic Health Records and Medical Claims Data to Support Regulatory Decision-Making for Drug and Biological Products. <https://www.fda.gov/media/152503/download>
31. FDA. (2023). Guidance for Industry: Real-World Data: Assessing Registries to Support Regulatory Decision-Making for Drug and Biological Products. <https://www.fda.gov/media/154449/download>
32. FDA. (2023). Draft: Use of Real-World Evidence to Support Regulatory Decision-Making for Medical Devices. <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/draft-use-real-world-evidence-support-regulatory-decision-making-medical-devices>
33. FDA. (2023). Draft Guidance for Industry: Considerations for the Design and Conduct of Externally Controlled Trials for Drug and Biological Products. <https://www.fda.gov/media/164960/download>
34. FDA. (2024). Draft Guidance for Industry: Integrating Randomized Controlled Trials for Drug and Biological Products into Routine Clinical Practice Guidance for Industry. <https://www.fda.gov/media/181871/download>
35. FDA. (2024). Advancing the Use of Complex Innovative Designs in Clinical Trials: From Pilot to Practice. <https://www.fda.gov/news-events/advancing-use-complex-innovative-designs-clinical-trials-pilot-practice-03052024>
36. FDA. (2025). Model-Informed Drug Development Paired Meeting Program. <https://www.fda.gov/drugs/development-resources/model-informed-drug-development-paired-meeting-program>
37. FDA. (2024). Complex Innovative Trial Design Meeting Program. <https://www.fda.gov/drugs/development-resources/complex-innovative-trial-design-meeting-program>
38. FDA. (2025). Advancing Real-World Evidence Program. <https://www.fda.gov/drugs/development-resources/advancing-real-world-evidence-program>
39. Park J.J.H., O. Harari, L. Dron, R.T. Lester, K. Thorlund and E.J. Mills. (2020). An Overview of Platform Trials with a Checklist for Clinical Readers. *Journal of Clinical Epidemiology*, 125: 1-8. doi:10.1016/j.jclinepi.2020.04.025
40. Angus D.C., S. Berry, R.J. Lewis et al. (2020). The REMAP-CAP (Randomized Embedded Multifactorial Adaptive Platform for Community-Acquired Pneumonia) Study: Rationale and Design. *Annals ATS*, 17 (7): 879-91. doi:10.1513/AnnalsATS.202003-192SD
41. Li X., C. Lu, K. Broglio et al. (2022). Current Usage and Challenges of Master Protocols: Based on Survey Results by ASA BIOP Oncology Methodology Working Group Master Protocol Sub-team. *Annals of Translational Medicine*, 10 (18): 1036. doi:10.21037/atm-21-6139
42. Concato J., and J. Corrigan-Curay. (2022). Real-World Evidence: Where Are We Now? *New England Journal of Medicine*, 386 (18): 1680-82. doi:10.1056/NEJMp2200089
43. FDA. Real-World Evidence Submissions to the Center for Drug Evaluation and Research. Published online June 26, 2024. Accessed May 5, 2025. <https://www.fda.gov/science-research/real-world-evidence/real-world-evidence-submissions-center-drug-evaluation-and-research>
44. Purpura C.A., E.M. Garry, N. Honig, A. Case and J.A. Rassen. (2022). The Role of Real-World Evidence in FDA-Approved New Drug and Biologics License Applications. *Clinical Pharmacology & Therapeutics*, 111 (1): 135-44. doi:10.1002/cpt.2474
45. U.S. Congress. (2022). 42 U.S.C. 1320f-1: Selection of Negotiation-Eligible Drugs as Selected Drugs. Vol 42.
46. Goldman D., J. Grogan, D. Lakdawalla, B. Liden and E. Trish. (2023). Mitigating the Inflation Reduction Act's Adverse Impacts on the Prescription Drug Market. doi:10.25549/q1nw-an61
47. Price D., and J. Scott. (2021). The U.S. Food and Drug Administration's Complex Innovative Trial Design Pilot Meeting Program: Progress to Date. *Clinical Trials*, 18 (6): 706-10. doi:10.1177/17407745211050580
48. FDA. (2023). Draft Guidance for Industry: Formal Meetings Between the FDA and Sponsors or Applicants of PDUFA Products. <https://www.fda.gov/media/172311/download>
49. Silva P., N. Janjan, K. S. Ramos et al. (2023). External Control Arms: COVID-19 Reveals the Merits of Using Real World Evidence in Real-Time for Clinical and Public Health Investigations. *Frontiers in Medicine*, 10: 1198088. doi:10.3389/fmed.2023.1198088
50. Jahanshahi M., K. Gregg, G. Davis et al. (2021). The Use of External Controls in FDA Regulatory Decision Making. *Therapeutic Innovation & Regulatory Science*, 55 (5): 1019-35. doi:10.1007/s43441-021-00302-y
51. Hattswell A.J., G. Baio, J.A. Berlin, A. Irs and N. Freemantle. (2016). Regulatory Approval of Pharmaceuticals Without a Randomised Controlled Study: Analysis of EMA and FDA Approvals 1999-2014. *BMJ Open*, 6 (6): e011666. doi:10.1136/bmjopen-2016-011666

52. FDA. (2023). Draft Guidance for Industry: Considerations for the Design and Conduct of Externally Controlled Trials for Drug and Biological Products. <https://www.fda.gov/media/164960/download>
53. FDA. (2023). Draft Guidance for Industry: Master Protocols for Drug and Biological Product Development. <https://www.fda.gov/media/174976/download>
54. FDA/CDRH. (2016). Patient Preference Information: Voluntary Submission, Review in Premarket Approval Applications, Humanitarian Device Exemption Applications, and De Novo Requests, and Inclusion in Decision Summaries and Device Labeling. <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/patient-preference-information-voluntary-submission-review-premarket-approval-applications>
55. 114th Congress. (2015-2016). H.R.34: 21st Century Cures Act. <https://www.congress.gov/bill/114th-congress/house-bill/34>
56. FDA. (2024). Incorporating Voluntary Patient Preference Information Over the Total Product Life Cycle. <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/incorporating-voluntary-patient-preference-information-over-total-product-life-cycle>
57. Rincon-Gonzalez L., W. K. D. Selig, B. Hauber et al. (2023). Leveraging Patient Preference Information in Medical Device Clinical Trial Design. *Therapeutic Innovation & Regulatory Science*, 57 (1): 152-59. doi:10.1007/s43441-022-00450-9.
58. MDIC. (2022). Using Patient Preference Information in the Design of Clinical Trials Framework. <https://mdic.org/resource/using-patient-preference-information-in-the-design-of-clinical-trials-framework>
59. Chaudhuri S.E., M. P. Ho, T. Irony, M. Sheldon and A.W. Lo. (2018). Patient-Centered Clinical Trials. *Drug Discovery Today*, 23 (2): 395-401. doi:10.1016/j.drudis.2017.09.016
60. Chaudhuri S.E., Z. Ben Chaouch, B. Hauber et al. (2023). Use of Bayesian Decision Analysis to Maximize Value in Patient-Centered Randomized Clinical Trials in Parkinson's Disease. *Journal of Biopharmaceutical Statistics*, 1-20. doi:10.1080/10543406.2023.2170400.
61. Guidance for Industry: FDA. (2024). Real-World Data: Assessing Electronic Health Records and Medical Claims Data to Support Regulatory Decision-Making for Drug and Biological Products. <https://www.fda.gov/media/152503/download>
62. HHS. (2013). 45 CFR 164.514: Other Requirements Relating to Uses and Disclosures of Protected Health Information. Vol 45.
63. FDA. (2023). Guidance for Industry: Considerations for the Use of Real-World Data and Real-World Evidence to Support Regulatory Decision-Making for Drug and Biological Products. <https://www.fda.gov/media/171667/download>
64. FDA. (2016). 21 CFR 314.50: Content and Format of an NDA. Vol 21.
65. Messick H. (2022). How a European Data Law Is Impacting FDA. FDA. <https://www.fda.gov/international-programs/global-perspective/how-european-data-law-impacting-fda>
66. Grandinetti C., D. R. Rivera, L. Pai-Scherf et al. (2025). Keeping the End in Mind: Reviewing U.S. FDA Inspections of Submissions Including Real-World Data. *Therapeutic Innovation & Regulatory Science*, 1-7. doi:10.1007/s43441-025-00791-1
67. Liu F., and D. Panagiotakos. (2022). Real-World Data: A Brief Review of the Methods, Applications, Challenges and Opportunities. *BMC Medical Research Methodology*, 22 (1): 287. doi:10.1186/s12874-022-01768-6.
68. ISO. (2018). 14644-12:2018: Cleanrooms and Associated Controlled Environments. <https://www.iso.org/standard/69432.html>
69. ISO (2020). 14155: Clinical Investigation of Medical Devices for Human Subjects: Good Clinical Practice. <https://www.iso.org/standard/71690.html>
70. FDA. (2023). Guidance for Industry: Data Standards for Drug and Biological Product Submissions Containing Real-World Data. <https://www.fda.gov/media/153341/download>
71. U.S. Congress. (2017). 21 USC 379k-1: Electronic Format for Submissions. Vol 21. <https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title21-section379k-1&num=0&edition=prelim>
72. Thorne N., and K. Wu. (2020). Data Standards Used for Electronic Submission of Real-World Evidence in New Drug Application. https://phuse.s3.eu-central-1.amazonaws.com/Archive/2020/Connect/US/Virtual/PAP_SA03.pdf
73. Garza M., G. Del Fiol, J. Tenenbaum, A. Walden and M. N. Zozus. (2016). Evaluating Common Data Models for Use With a Longitudinal Community Registry. *Journal of Biomedical Informatics*, 64: 333-41. doi:10.1016/j.jbi.2016.10.016
74. GAO. (2024). Report to Congressional Committees: FDA Has Steps Underway to Strengthen Coordination of Activities Supporting Drug Development. <https://www.gao.gov/assets/gao-25-106774.pdf>
75. Stecker J. (2024). Opinion: The FDA Could Help Save My Son From a Rare Disease. *Wall Street Journal*, February 27. <https://www.wsj.com/articles/the-fda-could-help-save-my-son-from-a-rare-disease-bureaucracy-efficacy-7090ac82>
76. Yang G., I. Cintina, A. Pariser, E. Oehrlein, J. Sullivan and A. Kennedy. (2022). The National Economic Burden of Rare Disease in the United States in 2019. *Orphanet Journal of Rare Diseases*, 17 (1): 163. doi:10.1186/s13023-022-02299-5
77. Li Y., and R. Izem. (2022). Novel Clinical Trial Design and Analytic Methods to Tackle Challenges in Therapeutic Development in Rare Diseases. *Annals of Translational Medicine*, 10 (18): 1034. doi:10.21037/atm-21-5496

78. Berry S. A., C. R. Coughlin, S. McCandless et al. (2020). Developing Interactions With Industry in Rare Diseases: Lessons Learned and Continuing Challenges. *Genetics in Medicine* 22 (1): 219-26. doi:10.1038/s41436-019-0616-9
79. NIH. (2022). FDA and NIH launch Public-Private Partnership for Rare Neurodegenerative Diseases. September 14. <https://www.ninds.nih.gov/news-events/press-releases/fda-and-nih-launch-public-private-partnership-rare-neurodegenerative-diseases>
80. FDA. (2024). Support for Clinical Trials Advancing Rare Disease Therapeutics (START) Pilot Program. FDA. <https://www.fda.gov/science-research/clinical-trials-and-human-subject-protection/support-clinical-trials-advancing-rare-disease-therapeutics-start-pilot-program>
81. FDA. (2024). Rare Disease Endpoint Advancement Pilot Program. <https://www.fda.gov/drugs/development-resources/rare-disease-endpoint-advancement-pilot-program>
82. FDA. (2025). FDA Rare Disease Innovation Hub. <https://www.fda.gov/industry/medical-products-rare-diseases-and-conditions/fda-rare-disease-innovation-hub>
83. FDA. (2019). Draft Guidance for Industry: Demonstrating Substantial Evidence of Effectiveness for Human Drug and Biological Products. <https://www.fda.gov/media/133660/download>
84. Janiaud P., T. Irony, E. Russek-Cohen and S. N. Goodman. (2021). U.S. Food and Drug Administration Reasoning in Approval Decisions When Efficacy Evidence Is Borderline, 2013–2018. *Annals of Internal Medicine*, 174 (11): 1603–11. doi:10.7326/M21-2918
85. FDA. (2023). 21 CFR 10.115(g): Good Guidance Practices. Vol 21.
86. FDA. (2023). Guidance for Industry: Rare Diseases: Considerations for the Development of Drugs and Biological Products. <https://www.fda.gov/media/119757/download>
87. FDA. (2018). Draft Guidance for Industry: Rare Diseases: Early Drug Development and the Role of Pre-IND Meetings Guidance for Industry. <https://www.fda.gov/media/117322/download>
88. FDA. (2019). Draft Guidance: Rare Diseases: Natural History Studies for Drug Development Guidance for Industry. <https://www.fda.gov/media/122425/download>
89. Pitts P.J. (2024). The Biggest Challenge Facing the FDA's New Rare Disease Innovation Hub. *STAT*, October 17. <https://www.statnews.com/2024/10/17/rare-disease-innovation-hub-fda-cber-cder-silos>
90. Cavazzoni P., and P. Marks. (2024). FDA Rare Disease Innovation Hub to Enhance and Advance Outcomes for Patients. <https://www.fda.gov/news-events/fda-voices/fda-rare-disease-innovation-hub-enhance-and-advance-outcomes-patients>
91. Rincon-Gonzalez L., W.K.D. Selig, B. Hauber et al. (2023). Leveraging Patient Preference Information in Medical Device Clinical Trial Design. *Therapeutic Innovation & Regulatory Sciences*, 57 (1): 152–59. doi:10.1007/s43441-022-00450-9
92. U.S. Congress. (2007). 21 U.S.C. 355: Risk Evaluation and Mitigation Strategies. Vol 21.
93. U.S. Congress. (2010). 42 U.S.C 262: Licensure of Biological Products as Biosimilar or Interchangeable. Vol 42.
94. FDA. (2023). Guidance for Industry: Benefit-Risk Assessment for New Drug and Biological Products. <https://www.fda.gov/media/152544/download>
95. Woodcock J., and P. Marks. (2019). Drug Regulation in the Era of Individualized Therapies. *New England Journal of Medicine*, 381 (17): 1678–80. doi:10.1056/NEJMe1911295
96. FDA. (2021). IND Submissions for Individualized Antisense Oligonucleotide Drug Products: Administrative and Procedural Recommendations Guidance for Sponsor-Investigators. <https://www.fda.gov/media/144872/download>
97. FDA. (2021). FDA Takes Steps to Provide Clarity on Developing New Drug Products in the Age of Individualized Medicine. <https://www.fda.gov/news-events/press-announcements/fda-takes-steps-provide-clarity-developing-new-drug-products-age-individualized-medicine>
98. FDA. (2004). 21 CFR 312.7: Promotion of Investigational Drugs. Vol 21.
99. FDA. (2004). 21 CFR 312.8: Charging for Investigational Drugs Under an IND. Vol 21.
100. Eichler H.G., and F. Sweeney. (2018). The Evolution of Clinical Trials: Can We Address the Challenges of the Future? *Clinical Trials*, 15 (1_suppl): 27–32. doi:10.1177/1740774518755058
101. FDA. (2025). Rare Disease Innovation Hub Strategic Agenda 2025. <https://www.fda.gov/media/185144/download>
102. O'Connor D.J., P. Moss, M. Wood et al. (2025). The Rare Therapies Launchpad: A Pilot Program for Individualized Medicines in the UK. *Nature Medicine*, 31 (5): 1379–80. doi:10.1038/s41591-025-03547-4
103. U.S. Congress. (2022). 21 U.S.C. 356k: Platform Technologies. Vol 21.
104. FDA. (2024). Draft Guidance: Platform Technology Designation Program for Drug Development Guidance for Industry. <https://www.fda.gov/media/178938/download>
105. Weberpals J., and S.V. Wang. (2024). External Controls to Study Treatment Effects in Rare Diseases: Challenges and Future Directions. *Clinical Pharmacology & Therapeutics*, 116 (6): 1521–24. doi:10.1002/cpt.3443
106. Hattswell A.J., G. Baio, J.A. Berlin, A. Irs and N. Freemantle. (2016). Regulatory Approval of Pharmaceuticals Without a Randomised Controlled Study: Analysis of EMA and FDA Approvals 1999–2014. *BMJ Open*, 6 (6): e011666. doi:10.1136/bmjopen-2016-011666

107. NORD. (2023). Comment From National Organization for Rare Disorders. <https://www.regulations.gov/comment/FDA-2022-D-2983-0153>
108. FDA. (2019). Draft Guidance: Rare Diseases: Natural History Studies for Drug Development Guidance for Industry. <https://www.fda.gov/media/122425/download>
109. Woodcock J., and L.M. LaVange. (2017). Master Protocols to Study Multiple Therapies, Multiple Diseases, or Both. *New England Journal of Medicine*, 377 (1): 62-70. doi:10.1056/NEJMra1510062
110. FDA. (2019). Drug Shortages: Root Causes and Potential Solutions. <https://www.fda.gov/media/131130/download?attachment>
111. HHS. (2024). Policy Considerations to Prevent Drug Shortages and Mitigate Supply Chain Vulnerabilities in the United States. <https://aspe.hhs.gov/sites/default/files/documents/3a9df8acf50e7fda2e443f025d51d038/HHS-White-Paper-Preventing-Shortages-Supply-Chain-Vulnerabilities.pdf>
112. FDA. (2023). Report to Congress: Drug Shortages CY 2023. <https://www.fda.gov/media/179156/download?attachment=>
113. FDA. (2025). Current and Resolved Drug Shortages and Discontinuations Reported to FDA. <https://dps.fda.gov/drugshortages>
114. McGeeney J.D., E. McAden and A. Sertkaya. (2018). Analysis of Drug Shortages, 2018-2023. Eastern Research Group (ERG). https://aspe.hhs.gov/sites/default/files/documents/efa332939da2064fa2c132bb8e842bb5/Drug%20Shortages_Data%20Brief_Final_2025.01.10.pdf
115. McBride A., S. Hudson-DiSalle, J. Pilz et al. (2022). National Survey on the Effect of Oncology Drug Shortages in Clinical Practice: A Hematology Oncology Pharmacy Association Survey. *JCO Oncology Practice*, 18 (8): e1289-e1296. doi:10.1200/OP.21.00883
116. Alpert A., and M. Jacobson. (2019). Impact of Oncology Drug Shortages on Chemotherapy Treatment. *Clinical Pharmacology & Therapeutics*, 106 (2): 415-21. doi:10.1002/cpt.1390
117. Perrone M., and N. Forster. (2024). FDA Staffers Leave for Private Sector Jobs as the Agency Struggles With Inspections. AP News. September 6. <https://apnews.com/article/fda-inspections-drug-manufacturing-india-china-7b3a7e9b45bcc3aea86ce5bf781271f3>
118. GAO. Report to Congressional Committees: FDA Should Implement Strategies to Retain Its Inspection Workforce. *United States Government Accountability Office*. Published online November 2024. <https://www.gao.gov/assets/gao-25-106775.pdf>
119. McMorris Rogers C., B. Guthrie and M. Griffith. (2023). E&C Republicans Press FDA Over Inadequate Inspection of Drug Manufacturing in India and China. House Committee on Energy and Commerce. <https://energycommerce.house.gov/posts/e-and-c-republicans-press-fda-over-inadequate-inspection-of-drug-manufacturing-in-india-and-china>
120. GAO. (2022). Report to Congressional Requesters: FDA Should Take Additional Steps to Improve Its Foreign Inspection Program. United States Government Accountability Office. <https://www.gao.gov/assets/gao-22-103611.pdf>
121. Bednarski L., S. Roscoe, C. Blome and M. C. Schleper. (2023). Geopolitical Disruptions in Global Supply Chains: A State-of-the-Art Literature Review. *Production Planning & Control*, 36 (4): 536-62. doi:10.1080/09537287.2023.2286283
122. White House. (2025). Regulatory Relief to Promote Domestic Production of Critical Medicines. <https://www.whitehouse.gov/presidential-actions/2025/05/regulatory-relief-to-promote-domestic-production-of-critical-medicines>
123. FDA. (2025). FDA Announces Expanded Use of Unannounced Inspections at Foreign Manufacturing Facilities. <https://www.fda.gov/news-events/press-announcements/fda-announces-expanded-use-unannounced-inspections-foreign-manufacturing-facilities>
124. Mezher M. (2021). FDA Issues Long-Awaited Pandemic Remote Inspections Guidance. <https://www.raps.org/news-and-articles/news-articles/2021/4/fda-issues-long-awaited-pandemic-remote-inspection>
125. FDA. (2024). Draft Guidance for Industry: Conducting Remote Regulatory Assessments: Questions and Answers. <https://www.fda.gov/media/160173/download>
126. FDA. (2023). Draft Guidance for Industry: Remote Interactive Evaluations of Drug Manufacturing and Bioresearch Monitoring Facilities Guidance for Industry. <https://www.fda.gov/media/173286/download>
127. Califf R.M., and J. Jones. (2024). FDA's Unified Human Foods Program, New Model for Field Operations, and Other Modernization Efforts Go Into Effect. <https://www.fda.gov/news-events/press-announcements/fdas-unified-human-foods-program-new-model-field-operations-and-other-modernization-efforts-go>
128. Al-Faruke F. (2024). FDA Leaders Detail Reorg Plans, Say 1,500 ORA Staff Will Be Reassigned. *Regulatory Focus*. <https://www.raps.org/News-and-Articles/News-Articles/2024/1/FDA-leaders-detail-reorg-plans,-say-1,500-ORA-staf>
129. FDA. (2022). Modernization in Action 2022. https://www.fda.gov/files/about%20fda/published/Modernization_in_Action_2022.pdf
130. ICMRA. (2025). ICMRA Collaborative Hybrid Inspection Pilot (CHIP) Summary Report. <https://www.gmp-compliance.org/gmp-news/icmra-publishes-hybrinspection-pilot-summary-report>
131. U.S. Congress. (2022). 21 U.S.C. 374(g): Inspections by Accredited Persons. Vol 21.
132. Pharmtech. (2025). Regulating Innovation, Quality, and Risk. *Pharmaceutical Technology*. <https://www.e-ditionaleditions.com/i/1514991-pharmaceutical-technology-january-2024>

133. Medina C., and F. Richmond. (2015). Incentivizing Quality in the Manufacture of Pharmaceuticals: Industry Views on Quality Metrics and Ratings. *Therapeutic Innovation & Regulatory Science*, 49 (5): 730-38. doi:10.1177/2168479015589821
134. U.S. Congress. (2022). 21 U.S.C. 360(h)(3-4): Registration of Producers of Drugs or Devices. Vol 21
135. FDA. (2024). Advanced Manufacturing: FDA News, Events, and Funding Opportunities Related to Advanced Manufacturing. <https://www.fda.gov/emergency-preparedness-and-response/mcm-issues/advanced-manufacturing>
136. GAO. (2023). Report to Congressional Committees: FDA Should Fully Assess Its Efforts to Encourage Innovation. <https://www.gao.gov/assets/gao-23-105650.pdf>
137. FDA. (2023). Guidance for Industry: Q13 Continuous Manufacturing of Drug Substances and Drug Products. <https://www.fda.gov/media/165775/download>
138. FDA. (2023). Discussion Paper: Artificial Intelligence in Drug Manufacturing. <https://www.fda.gov/media/165743/download?attachment>
139. U.S. Congress. (2017). 21 U.S.C. 356i: Prompt Reports of Marketing Status. Vol 21.
140. FDA. (2023). Accelerated Approval. <https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/accelerated-approval>
141. FDA. (2021). The History of FDA's Role in Preventing the Spread of HIV/AIDS. <https://www.fda.gov/about-fda/fda-history-exhibits/history-fdas-role-preventing-spread-hiv-aids>
142. FDA. (2014). Guidance for Industry: Expedited Programs for Serious Conditions—Drugs and Biologics. <https://www.fda.gov/media/86377/download>
143. FDA. (2024). Draft Guidance for Industry: Expedited Program for Serious Conditions—Accelerated Approval of Drugs and Biologics. <https://www.fda.gov/media/184120/download>
144. U.S. Congress. (2022). 21 U.S.C. 356c: Discontinuance or Interruption in the Production of Life-Saving Drugs. Vol 21.
145. Emmott N, D'Ambrosio M, Locke T, Hendricks-Sturup R. Applying Real-World Data and Real-World Evidence for Accelerated Approvals and Coverage Decisions. *Duke Margolis Institute for Health Policy*. Published online July 25, 2024. <https://healthpolicy.duke.edu/sites/default/files/2024-07/RWD%20RWE%20for%20Accelerated%20Approvals%20and%20Coverage.pdf>
146. Kaltenboeck A., A. Mehlman and S.D. Pearson. (2021). Strengthening the Accelerated Approval Pathway: An Analysis of Potential Policy Reforms and Their Impact on Uncertainty, Access, Innovation, and Costs. Institute for Clinical and Economic Review. https://icer.org/wp-content/uploads/2021/04/Strengthening-the-Accelerated-Approval-Pathway_-_ICER-White-Paper_-_April-2021.pdf
147. Beakes-Read G., M. Neisser, P. Frey and M. Guarducci. (2022). Analysis of FDA's Accelerated Approval Program Performance December 1992–December 2021. *Therapeutic Innovation & Regulatory Science*, 56 (5): 698-703. doi:10.1007/s43441-022-00430-z
148. Flanagan, K. (2021). Congress Should Fix FDA's Accelerated Approval for the Next 30 Years. *STAT*, August 12. <https://www.statnews.com/2021/08/12/congress-fix-accelerated-approval-program-for-next-30-years>
149. Kakkis E. D. (2025). Aduhelm's Accelerated Approval Offers a Promising Roadmap for Rare Diseases. *STAT*, July 7. <https://www.statnews.com/2021/07/07/accelerated-approval-aduhelm-promising-roadmap-rare-diseases>
150. Gyawali B., J. S. Ross and A. S. Kesselheim. (2021). Fulfilling the Mandate of the US Food and Drug Administration's Accelerated Approval Pathway: The Need for Reforms. *JAMA Internal Medicine*, 181 (10): 1275-76. doi:10.1001/jamainternmed.2021.4604
151. HHS. (2022). Office of Inspector General Data Snapshot: Delays in Confirmatory Trials for Drug Applications Granted FDA's Accelerated Approval Raise Concerns. <https://oig.hhs.gov/oei/reports/OEI-01-21-00401.pdf>
152. HHS. (2025). How FDA Used Its Accelerated Approval Pathway Raised Concerns in 3 of 24 Drugs Reviewed. <https://oig.hhs.gov/documents/evaluation/10160/OEI-01-21-00400.pdf>
153. CMS. (2022). Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease. <https://www.cms.gov/medicare-coverage-database/view/ncacal-decision-memo.aspx?proposed=N&ncaid=305>
154. Saltzman J. (2021). 'This is unprecedented': Several Private Insurers Won't Cover Biogen's Alzheimer's Drug. *STAT*, July 14. <https://www.statnews.com/2021/07/14/this-is-unprecedented-several-private-insurers-wont-cover-biogens-alzheimers-drug>
155. Herman B. (2022). UnitedHealthcare restricts coverage of Aduhelm, following Medicare. *STAT*, May 2. <https://www.statnews.com/2022/05/02/unitedhealthcare-restricts-coverage-of-aduhelm-following-medicare>
156. U.S. Congress. (2022). 21 U.S.C. 356-2: Accelerated Approval Council. Vol 21.
157. FDA. (2025). Accelerated Approval and Considerations for Determining Whether a Confirmatory Trial Is Underway: Guidance for Industry. <https://www.fda.gov/media/184831/download>
158. FDA. (2025). Accelerated Approval Council Activities Report CY 2024. <https://www.fda.gov/media/174154/download>
159. Galson S., and G. Simon. (2016). Discussion Paper: Real-World Evidence to Guide the Approval and Use of New Treatments. *Real-World Evidence Generation and Evaluation of Therapeutics: Proceedings of a Workshop*. National Academies Press. <https://www.ncbi.nlm.nih.gov/books/NBK441699>

160. Wallach J. D., A. D. Zhang, J. J. Skydel et al. (2021). Feasibility of Using Real-World Data to Emulate Postapproval Confirmatory Clinical Trials of Therapeutic Agents Granted US Food and Drug Administration Accelerated Approval. *JAMA Network Open*, 4 (11): e2133667. doi:10.1001/jamanetworkopen.2021.33667
161. AETION. (2024). Whitepaper: RWE as Confirmatory Evidence for Accelerated Approvals. <https://evidence-hub.aetion.com/rwe-as-confirmatory-evidence-for-accelerated-approvals>
162. Mehta G. U., and R. Pazdur. (2024). Oncology Accelerated Approval Confirmatory Trials: When a Failed Trial Is Not a Failed Drug. *Journal of Clinical Oncology*, 42 (32). doi:10.1200/JCO-24-01654
163. FDA. (2024). Learn About FDA Advisory Committees. <https://www.fda.gov/patients/learn-about-fda-advisory-committees>
164. Helms Williams E.C., N.N. Bumpus and R.M. Califf. (2024). The Role of FDA Advisory Committees. *Nature Medicine*, 30 (11): 3050-52. doi:10.1038/s41591-024-03242-w
165. Ramachandran R., J.S. Ross, J.S. Etkin and J.L. Schwartz. (2024). The Future of FDA Advisory Committees: Protecting Public Health and Preserving Public Trust. doi:10.1377/forefront.20240628.510062
166. Al-Faruque F. (2023). FDA's Marks Weighs in on Adcomm Reform. *Regulatory Focus*. <https://www.raps.org/News-and-Articles/News-Articles/2023/7/FDA%E2%80%99s-Marks-weighs-in-on-adcomm-reform>
167. Daval C.J.R., T.W. Teng, M. Russo and A.S. Kesselheim. (2023). Association of Advisory Committee Votes With US Food and Drug Administration Decision-Making on Prescription Drugs, 2010-2021. *JAMA Health Forum*, 4 (7): e231718. doi:10.1001/jamahealthforum.2023.1718
168. Kanter G. P. (2023). The Real Question the FDA Is Asking Its Advisory Committees. *JAMA Health Forum*, 4 (7): e231234. doi:10.1001/jamahealthforum.2023.1234
169. FDA. (2008). Guidance for Industry Advisory Committee Meetings—Preparation and Public Availability of Information Given to Advisory Committee Members.
170. McCaughan M. (2022). US FDA's ODAC Pushes Back Against 'Leading' Questions. Citeline. <https://insights.citeline.com/PS147119/US-FDAs-ODAC-Pushes-Back-Against-Leading-Questions>
171. U.S. Congress. (2008). 42 U.S.C. 1395y: Exclusions from Coverage and Medicare as Secondary Payer. Vol 42.
172. CMS. (2023). HHS Secretary Responds to the President's Executive Order on Drug Prices. <https://www.cms.gov/newsroom/press-releases/hhs-secretary-responds-presidents-executive-order-drug-prices>
173. CMS. (2023). CMS Innovation Center's One-Year Update on the Executive Order to Lower Prescription Drug Costs for Americans. <https://www.cms.gov/blog/cms-innovation-centers-one-year-update-executive-order-lower-prescription-drug-costs-americans>
174. Grogan J. (2022). CMS's Alzheimer's Coverage Policy Will Inhibit Access and Discourage Innovation. USC Schaeffer Institute Public Policy & Government Service. <https://schaeffer.usc.edu/research/cmss-alzheimers-coverage-policy-will-inhibit-access-and-discourage-innovation>
175. Bipartisan House Task Force on Artificial Intelligence. (2024). Bipartisan House Task Force Report on Artificial Intelligence. <https://www.speaker.gov/wp-content/uploads/2024/12/AI-Task-Force-Report-FINAL.pdf>
176. White House. (2025). Executive Order 14179: Removing Barriers to American Leadership in Artificial Intelligence. <https://www.whitehouse.gov/presidential-actions/2025/01/removing-barriers-to-american-leadership-in-artificial-intelligence>
177. FDA. (2019). FDA's Technology Modernization Action Plan. <https://www.fda.gov/about-fda/reports/fdas-technology-modernization-action-plan>
178. FDA. (2022). Modernization in Action 2022: Technology Modernization Action Plan (TMAP) and Data Modernization Action Plan (DMAP) Anniversary Report. https://www.fda.gov/files/about%20fda/published/Modernization_in_Action_2022.pdf
179. FDA. (2024). Guidance for Industry and Food and Drug Administration Staff: Marketing Submission Recommendations for a Predetermined Change Control Plan for Artificial Intelligence-Enabled Device Software Functions. <https://www.fda.gov/media/166704/download>
180. FDA. (2023). Discussion Paper and Request for Feedback: Using Artificial Intelligence & Machine Learning in the Development of Drug & Biological Products. <https://www.fda.gov/media/167973/download>
181. FDA. (2021). Data Modernization Action Plan. <https://www.fda.gov/media/143627/download?attachment>
182. FDA. (2022). Enterprise Modernization Action Plan (EMAP). <https://www.fda.gov/media/158206/download?attachment>
183. FDA. (2022). Cybersecurity Modernization Action Plan. <https://www.fda.gov/media/163086/download?attachment>
184. Faust J. (2025). A Conversation with FDA Commissioner Marty Makary. *MedPage Today*. <https://www.medpagetoday.com/opinion/faustfiles/11532>
185. FDA. (2025). FDA Announces Completion of First AI-Assisted Scientific Review Pilot and Aggressive Agency-Wide AI Rollout Timeline. FDA. <https://www.fda.gov/news-events/press-announcements/fda-announces-completion-first-ai-assisted-scientific-review-pilot-and-aggressive-agency-wide-ai>
186. FDA. (2022). The FDA Moves Into Third Phase of Artificial Intelligence Imported Seafood Pilot Program. <https://www.fda.gov/food/hfp-constituent-updates/fda-moves-third-phase-artificial-intelligence-imported-seafood-pilot-program>
187. Schneider M.E. (2021). Review Highlights Lack of Consistency in FDA's 'Close Call' Approvals. <https://www.raps.org/news-and-articles/news-articles/2021/9/review-highlights-lack-of-consistency-in-fdas-clos>

188. Janiaud P., T. Irony, E. Russek-Cohen and S.N. Goodman. (2021). U.S. Food and Drug Administration Reasoning in Approval Decisions When Efficacy Evidence Is Borderline, 2013–2018. *Annals of Internal Medicine*, 174 (11): 1603–11. doi:10.7326/M21-2918
189. Gottlieb S., and L. Silvis. (2023). Regulators Face Novel Challenges as Artificial Intelligence Tools Enter Medical Practice. *JAMA Health Forum*, 4 (6): e232300. doi:10.1001/jamahealthforum.2023.2300
190. FDA. (2021). Artificial Intelligence/Machine Learning (AI/ML)-Based Software as a Medical Device (SaMD) Action Plan. <https://www.fda.gov/media/145022/download?attachment>
191. Reader R. (2024). Artificial Intelligence Is Making Critical Health Care Decisions. The Sheriff Is MIA. Politico, February 18. <https://www.politico.com/news/2024/02/18/artificial-intelligence-health-care-fda-00141768>
192. FDA. (2024). Artificial Intelligence and Machine Learning (AI/ML)-Enabled Medical Devices. <https://www.fda.gov/medical-devices/software-medical-device-samd/artificial-intelligence-and-machine-learning-aiml-enabled-medical-devices>
193. FDA. (2025). Artificial Intelligence-Enabled Device Software Functions: Lifecycle Management and Marketing Submission Recommendations. <https://www.fda.gov/media/184856/download>
194. FDA. (2025). Considerations for the Use of Artificial Intelligence to Support Regulatory Decision-Making for Drug and Biological Products. <https://www.fda.gov/media/184830/download>
195. Pecci A. (2024). FDA Chief Says Agency Can't Manage Health Tech Alone. PharmaVoice. <https://www.pharmavoice.com/news/robert-califf-fda-commissioner-ai-machine-learning-pharma/704495>
196. Califf R. (2024). Remarks by FDA Commissioner Robert M. Califf to the Coalition for Health AI (CHAI). <https://www.fda.gov/news-events/speeches-fda-officials/remarks-fda-commissioner-robert-m-califf-coalition-health-ai-chai-03052024>
197. Schumaker E., R. King, C. Paun, R. Reader and D. Payne. (2024). The AI Assurance Labs Are Coming. Politico, September 18. <https://www.politico.com/newsletters/future-pulse/2024/09/18/the-ai-assurance-labs-are-coming-00179662>
198. Ehrenfeld J.M., and K.F. Woeltje. (2024). The Challenges of Establishing Assurance Labs for Health Artificial Intelligence (AI). *Journal of Medical Systems*, 48 (1): 110. doi:10.1007/s10916-024-02127-2
199. Ross C. (2024). Republican Lawmakers Criticize FDA's Partnership With CHAI on Regulating AI in Medicine. *STAT*, June 18. <https://www.statnews.com/2024/06/18/chai-fda-lawmakers-criticize-regulation-ai-medicine>
200. FDA. (2024). 510(k) Third Party Review Program. <https://www.fda.gov/medical-devices/premarket-submissions-selecting-and-preparing-correct-submission/510k-third-party-review-program>
201. Miller B.J., W. Blanks and B. Yagi. (2023). The 510(k) Third Party Review Program: Promise and Potential. *Journal of Medical Systems*, 47 (1): 93. doi:10.1007/s10916-023-01986-5
202. FDA. (2022). Guidance for Industry and Food and Drug Administration Staff: Clinical Decision Support Software.
203. Cassidy B. (2024). Ranking Member Cassidy Rebukes FDA Policy Limiting Access to Innovative Medical Technology. <https://www.help.senate.gov/rep/newsroom/press/ranking-member-cassidy-rebukes-fda-policy-limiting-access-to-innovative-medical-technology>
204. Zarzecki L. (2024). AdvaMed: FDA Should Oversee Health AI, but Narrow 'Device' Definition. Inside Health Policy, May 20. <https://insidehealthpolicy.com/daily-news/advamed-fda-should-oversee-health-ai-narrow-device-definition>
205. Gottlieb S. (2025). New FDA Policies Could Limit the Full Value of AI in Medicine. *JAMA Health Forum*, 6 (2): e250289. doi:10.1001/jamahealthforum.2025.0289
206. Jing X., L. Himawan and T. Law. (2019). Availability and Usage of Clinical Decision Support Systems (CDSSs) in Office-Based Primary Care Settings in the USA. *BMJ Health & Care Informatics*, 26 (1): e100015. doi:10.1136/bmjhci-2019-100015
207. Goh E., R. Gallo, J. Hom et al. (2024). Large Language Model Influence on Diagnostic Reasoning: A Randomized Clinical Trial. *JAMA Network Open*, 7 (10): e2440969. doi:10.1001/jamanetworkopen.2024.40969
208. U.S. Congress. (2016). 21 U.S.C. 360j(o): Regulation of Medical and Certain Decisions Support Software. Vol. 21.
209. U.S. Congress. (2016). 21 U.S.C. 360j(o)(1)(E): Regulation of Medical and Certain Decisions Support Software. Vol 21.
210. Gliadkovskaya A. (2024). Some Doctors Are Using ChatGPT to Assist with Clinical Decisions. Is It Safe? Fierce Healthcare. <https://www.fiercehealthcare.com/special-reports/some-doctors-are-using-public-generative-ai-tools-chatgpt-clinical-decisions-it>
211. Gottlieb S. (2018). Opening Remarks for Part 15 Public Meeting on Generic Drug Competition. FDA. <https://www.fda.gov/news-events/speeches-fda-officials/opening-remarks-part-15-public-meeting-generic-drug-competition-07182018>
212. FDA. (2025). FDA Drug Competition Action Plan. <https://www.fda.gov/drugs/guidance-compliance-regulatory-information/fda-drug-competition-action-plan>
213. FDA. (2024). Biosimilars Action Plan. <https://www.fda.gov/drugs/biosimilars/biosimilars-action-plan>
214. U.S. Congress. Drug Price Competition and Patent Term Restoration Act of 1984.
215. U.S. Congress. Patient Protection and Affordable Care Act of 2010.
216. U.S. Congress. (2022). 21 U.S.C. 355(j): Abbreviated New Drug Applications. Vol. 21.

217. U.S. Congress. (2010). 42 U.S.C 262(k): Licensure of Biological Products as Biosimilar or Interchangeable. Vol 42.
218. FDA. (2024). Generic Drugs: Questions & Answers. <https://www.fda.gov/drugs/frequently-asked-questions-popular-topics/generic-drugs-questions-answers>
219. U.S. Congress. (2019). 42 U.S.C. 262(i): “Biological Product” Defined. Vol 42.
220. FDA. (2024). Biosimilars Info Sheet Level 1: Foundational Concepts. <https://www.fda.gov/media/154912/download>
221. Association for Accessible Medicines. (2024). U.S. Generic & Biosimilar Medicines Savings Report. <https://accessiblemeds.org/wp-content/uploads/2025/01/AAM-2024-Generic-Biosimilar-Medicines-Savings-Report.pdf>
222. IQVIA Institute for Human Data Science. (2024). The Use of Medicines in the U.S. 2024: Usage and Spending Trends and Outlook to 2028. <https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/the-use-of-medicines-in-the-us-2024>
223. Conrad R., and L. Randall. (2019). Generic Competition and Drug Prices: New Evidence Linking Greater Generic Competition and Lower Generic Drug Prices Report. <https://www.fda.gov/media/133509/download>
224. IQVIA Institute for Human Data Science. (2023). Biosimilars in the United States 2023-2027. <https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/biosimilars-in-the-united-states-2023-2027>
225. FDA. (2024). FDA Drug Competition Action Plan: Maximizing Scientific and Regulatory Clarity With Respect to Complex Generic Drugs. <https://www.fda.gov/drugs/guidance-compliance-regulatory-information/fda-drug-competition-action-plan-maximizing-scientific-and-regulatory-clarity-respect-complex>
226. FDA. (2025). Product-Specific Guidances for Generic Drug Development. <https://www.fda.gov/drugs/guidances-drugs/product-specific-guidances-generic-drug-development>
227. FDA. (2024). FDA Drug Competition Action Plan: Improving the Efficiency of the Generic Drug Development, Review, and Approval Process. <https://www.fda.gov/drugs/guidance-compliance-regulatory-information/fda-drug-competition-action-plan-improving-efficiency-generic-drug-development-review-and-approval>
228. FDA. (2017). FDA Tackles Drug Competition to Improve Patient Access. <https://www.fda.gov/news-events/press-announcements/fda-tackles-drug-competition-improve-patient-access>
229. FDA. (2022). Prioritization of the Review of Original ANDAs, Amendments, and Supplements. <https://www.fda.gov/media/89061/download>
230. U.S. Congress. (2003). 21 U.S.C. 355(j)(5)(B)(Iv): 180-Day Exclusivity Period. Vol 21.
231. Seshamani M. (2024). Medicare Drug Price Negotiation Program: Final Guidance, Implementation of Sections 1191–1198 of the Social Security Act for Initial Price Applicability Year 2027 and Manufacturer Effectuation of the Maximum Fair Price in 2026 and 2027. CMS. <https://www.cms.gov/files/document/medicare-drug-price-negotiation-final-guidance-ipay-2027-and-manufacturer-effectuation-mfp-2026-2027.pdf>
232. Lanthier M. L., K. W. Kerr and K. L. Miller. (2019). An Analysis of Follow-On Development in New Drug Classes, January 1986–June 2018. *Clinical Pharmacology & Therapeutics*, 106 (5): 1125–32. doi:10.1002/cpt.1554
233. FDA. (2019). Guidance for Industry: Considerations in Demonstrating Interchangeability With a Reference Product. <https://www.fda.gov/media/124907/download>
234. European Medicines Agency. (2023). Statement on the Scientific Rationale Supporting Interchangeability of Biosimilar Medicines in the EU. https://www.ema.europa.eu/en/documents/public-statement/statement-scientific-rationale-supporting-interchangeability-biosimilar-medicines-eu_en.pdf
235. European Medicines Agency. (2023). Biosimilar Medicines: Overview. <https://www.ema.europa.eu/en/human-regulatory-overview/biosimilar-medicines-overview>
236. FDA. (2019). Clinical Immunogenicity Considerations for Biosimilar and Interchangeable Insulin Products. <https://www.fda.gov/media/133014/download>
237. FDA. (2025). FDA Purplebook. <https://purplebooksearch.fda.gov>
238. FDA. (2024). Considerations in Demonstrating Interchangeability With a Reference Product: Update. <https://www.fda.gov/media/179456/download>
239. FDA. (2024). Safety Outcomes When “Switching” Between Biosimilars and Reference Products. <https://www.fda.gov/drugs/spotlight-cder-science/safety-outcomes-when-switching-between-biosimilars-and-reference-products>